HTB

2015

EACS guidelines (2015): translations in 11 languages now available online

Recommendations for management of bone health in people living with HIV

Timing of very early ART to limit early HIV-related mucosal dysfunction

Broad CD8 T cell responses are required to overcome dominance of CTL escape in the latent HIV reservoir

Broadly neutralising antibody suppresses HIV in clinical trial

New clinical trial for extensively drug resistant TB (XDR-TB)

MSF report and call to action: Promising new TB drugs are not reaching patients

Sofosbuvir access: new patent challenges to sofosbuvir

Methmephangee – ChemSex vs recreational drug use: a proposed definition for health workers

WHO statement for public disclosure of clinical trial results

2015 Conference on Retroviruses and Opportunistic Infections (CROI), 23-26 February 2015, Seattle

Pre-CROI meetings and workshops

CROI webcasts online

March/April 2015: Volume 16 Number 3/4

Pipeline ART: tenofovir alafenamide (TAF)

Pipeline ART: maturation inhibitors and an attachment inhibitor

No HIV transmissions between gay couples when viral load is undetectable: preliminary results from “Opposites Attract” study in Australia, Thailand and Brazil

PrEP reduced HIV risk by at least 86% in PROUD: no transmissions likely from people taking meds

Q&A on the PROUD study and PrEP results from CROI

“On demand” PrEP dosing in IPERGAY: 86% reduced risk of HIV, no transmissions with active drug use

Other HIV PrEP studies at CROI 2015: implementation of oral PrEP and problems with tenofovir gel

Early HIV treatment and isoniazid prophylaxis: why TEMPRANO results do not yet support universal ART at CD4 counts >500

Unintended pregnancies with levonorgestrel implant due to drug interactions with efavirenz-based ART

Three drug ART best for preventing vertical transmission to infants: results from the PROMISE study

3 in 5 breastfeeding women with viral load >1,000 copies/mL are undiagnosed in Kenya, Malawi and South Africa

Point of care HIV PCR test for infant diagnosis: good performance but poorer results in youngest age group

Weekend-off ART is non-inferior to continuous ART in young people taking efavirenz-based regimens: results from BREATHER study

Increased cardiovascular risks in HIV positive children in Uganda and Zambia partially reversed by ART

Lopinavir/ritonavir superior to nevirapine in children <3 years old: IMPAACT P1060 five year results

Long-term safety and efficacy of tenofovir in children

UK case of HIV remission: ten years off-ART in patient with prior progression and treated during seroconversion

XXIV International HIV Drug Resistance Workshop
, 21-22 February 2015, Seattle, Washington

Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

FDA approves fixed dose darunavir/cobicistat

FDA approves fixed dose atazanavir/cobicistat

FDA approves fixed dose raltegravir/3TC formulation: Merck holds back from marketing in US

Recommendations for management of bone disease in HIV

FDA approves 9-valent HPV vaccine: active against types 6, 11, 16, 18, 31, 33, 45, 52 and 58

NHS further delays access to sofosbuvir

Public Health England outline plans to promote the health and wellbeing of gay and bisexual men

START study video

Diabetes in people with HIV: special issue of RITA

NAT report: Young MSM in the UK

Guidance on reporting results of clinical trials

March/April 2015: Volume 16 Number 3/4

Five Nations Conference on HIV and Hepatitis – 8-9 December 2014, London

Summary of the pre-conference clinical course

Hepatitis C drug access: Europe is the new Africa

January/February 2015: Volume 16 Number 1/2

45th Union World Conference on Lung Health, 28 October – 1 November 2014, Barcelona, Spain

Good outcomes within the National Bedaquiline Clinical Access programme in South Africa

Pharmacokinetics and safety of moxifloxacin in children

TB in the ARROW trial of children on ART

Problems giving current second line TB drugs to children

Morocco’s acceptance of EU patent law threatens millions of lives

Global Fund releases end-2104 numbers

Dolutegravir and Truimeq approved in England

London prescribing guidelines updated to include dolutegravir and Triumeq

Adequate cerebrospinal fluid exposure of efavirenz when dosed at 400 mg

Three drug regimen superior for preventing vertical transmission in the PROMISE study

CMV associated with 50% increased risk of non-AIDS related mortality in HIV positive people

Impact of smoking on life expectancy in HIV infection

Post navigation